Nkarta (NASDAQ:NKTX) Announces Earnings Results, Misses Estimates By $0.05 EPS

Nkarta (NASDAQ:NKTX) posted its quarterly earnings data on Thursday. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.05), FiscalAI reports.

Nkarta Stock Performance

Shares of NKTX traded up $0.16 during trading hours on Friday, hitting $1.73. The company had a trading volume of 2,000,682 shares, compared to its average volume of 1,137,618. The stock has a market capitalization of $123.90 million, a price-to-earnings ratio of -1.00 and a beta of 1.24. The firm has a fifty day moving average price of $2.34 and a 200-day moving average price of $2.51. Nkarta has a 52-week low of $1.48 and a 52-week high of $3.72.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on NKTX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nkarta in a research note on Monday, September 21st. HC Wainwright assumed coverage on shares of Nkarta in a report on Monday, November 2nd. They set a “buy” rating for the company. Wall Street Zen cut Nkarta from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Finally, Stifel Nicolaus cut their price target on Nkarta from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Nkarta currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.20.

Nkarta Company Profile

Nkarta, Inc is a clinical-stage biotechnology company focused on developing engineered natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s platform is designed to produce allogeneic, or donor-derived, NK cells that can be engineered with chimeric antigen receptors (CARs) to recognize and attack targeted cells.

Nkarta’s research and development programs have included NKX019, a CD19-targeted CAR NK-cell therapy investigated for B-cell malignancies and autoimmune disorders, and NKX101, an NKG2D-targeted CAR NK-cell therapy developed for certain solid tumors.